Showing 2691-2700 of 9825 results for "".
Exploring the Benefits of Nitric Oxide for Hair Loss Patients Through REVIAN® Red
https://practicaldermatology.com/topics/hair-nails/exploring-the-benefits-of-nitric-oxide-for-hair-loss-patients-through-revian-red/19753/Learn more about the mechanism of action of the new REVIAN Red Dual-Band LED light therapy cap and what makes it unique from other at-home FDA-cleared devices. REVIAN Red is indicated to treat androgenetic alopecia and to promote hair growth in males who have Norwood-Hamilton classifications of IIaOrchiectomy-Induced Melasma: Considering Melasma in Male Patients Post-Orchiectomy
https://practicaldermatology.com/topics/clinical-case-reports/orchiectomy-induced-melasma-considering-melasma-male-patients-post-orchiectomy/26663/Orchiectomy-Induced Melasma: Considering Melasma in Male Patients Post-OrchiectomyNoah Worcester 2024: Dr. Gold on Toxins
https://practicaldermatology.com/conferences/noah-worcester-2024/noah-worcester-2024-dr-gold-toxins/24583/Noah Worcester 2024: Dr. Gold on ToxinsDermWireTV: Meet Crown Aesthetics, Revance to Market Teoxane Fillers, Almirall Collaborates
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-meet-crown-aesthetics-revance-to-market-teoxane-fillers-almirall-collaborates/19719/On the heels of recent acquisitions, Crown Laboratories is reorganizing and rebranding as three divisions: Crown Aesthetics, Crown Beauty, and Crown Therapeutics. Revance gains immediate and exclusive rights to commercialize Teoxane’s RHA 2, RHA 3, and RHA 4 products, which include lidocaine. A fourRepresentation in Marketing and Outreach
https://practicaldermatology.com/series/diversity-and-equity-in-dermatology/representation-in-marketing-and-outreach/19916/There is an apparent low rate of participation in aesthetic procedures among patients of color. Does this reflect a lack of interest or does limited representation in marketing and educational materials leave patients feeling that aesthetic interventions aren't meant for them? Panelists discuss theGalderma, Allergan Rosacea News, Dupilumab Data
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-galderma-allergan-rosacea-news-dupilumab-data/18591/Galderma Laboratories launched a new pump dispenser design for Mirvaso (brimonidine) Topical Gel, 0.33. The FDA has accepted Allergan's New Drug Application (NDA) filing for oxymetazoline cream 1.0%, an investigational topical prescription product for the treatment of persistent facial erythema assoNew Treatment Option for Androgenetic Alopecia
https://practicaldermatology.com/series/c-suite-chats/new-treatment-option-for-androgenetic-alopecia/32969/Reid Waldman, MD, Co-Founder and CEO of Veradermics, discusses the prevalence of androgenetic alopecia-pattern hair loss and the company's investigational treatment candidate.Defining the Physician-Patient Relationship
https://practicaldermatology.com/topics/practice-management/defining-the-physician-patient-relationship/18928/In this edition of Derm Insider, Allan Wirtzer, MD and Cliff Lober, MD, JD talk to host Neal Bhatia, MD about the importance of defining the physician-patient relationship, determining when the relationship is established, and understanding the legal implications that come with that fiduciary or hei2020 Financial Benchmark Report: How Dermatology and Aesthetic Practices Fared in the COVID Era
https://practicaldermatology.com/topics/practice-management/2020-financial-benchmark-report-how-dermatology-and-aesthetic-practices-fared-in-the-covid-era/23693/How did your practice’s performance and growth compare to the rest of the industry?Hydroquinone in 2021
https://practicaldermatology.com/topics/pigmentary-disorders/hydroquinone-in-2021/23592/A year after OTC hydroquinone was pulled from the market as part of the CARES Act, a dermatologist discusses the effects on patient care.